Mind Your Meds

Edit Answers
12345678910111213141516171819
Across
  1. 3. Reduces myocardial oxygen demand primarily by decreasing preload through venous smooth muscle relaxation.
  2. 6. Dopamine antagonist whose use requires awareness of dose-dependent QT interval prolongation.
  3. 9. Maximum dosing is limited because of historical concerns regarding fluoride metabolite accumulation.
  4. 10. Irreversibly inhibits platelet function by acetylating cyclooxygenase, with effects lasting the lifespan of the platelet.
  5. 11. Enhances inhibitory neurotransmission by increasing the frequency of GABA-A receptor chloride channel opening.
  6. 12. Promotes intracellular potassium shift through β₂ receptor stimulation, making it useful beyond bronchodilation.
  7. 13. Competitive opioid antagonist that should be titrated to restore ventilation rather than full consciousness.
  8. 15. Remains indicated in one life-threatening ventricular dysrhythmia even when serum concentrations are normal.
  9. 16. Produces analgesia by inhibiting prostaglandin synthesis through reversible cyclooxygenase inhibition.
  10. 17. Class III antiarrhythmic that prolongs the myocardial action potential by blocking potassium channels.
  11. 18. Highly lipophilic μ-opioid agonist with rapid CNS penetration and minimal histamine release compared with morphine.
  12. 19. The only SAAS medication that produces clinically significant α₁, β₁ and β₂ receptor agonism in a single drug.
Down
  1. 1. Selective serotonin receptor antagonist associated with dose-dependent prolongation of the QT interval.
  2. 2. Exerts its therapeutic effects through altered gene transcription, explaining why clinical improvement is delayed.
  3. 3. Corrects neuroglycopenia but does not address the underlying cause of hypoglycaemia.
  4. 4. Produces dissociative anaesthesia primarily through antagonism of the NMDA receptor while generally preserving airway reflexes.
  5. 5. Reduces bleeding by preventing plasminogen activation rather than promoting clot formation.
  6. 7. Improves myocardial electrical stability during hyperkalaemia without reducing the serum potassium concentration.
  7. 8. May have limited effectiveness in patients with depleted hepatic glycogen stores despite appropriate dosing.
  8. 14. Increases heart rate by competitively inhibiting muscarinic receptors within the parasympathetic nervous system.